Date of Publication: 09-Mar-2026
INTELLIGENCE OVERVIEW
Agency: USFDA
The U.S. Food and Drug Administration (FDA) has released Revision 4 of the draft guidance titled “New and Revised Draft Q&As on Biosimilar Development and the BPCI Act.” This updated guidance provides further clarity on regulatory expectations for sponsors developing biosimilar products in the United States.
Biosimilars are biological products that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency. Their regulatory framework in the United States was established under the Biologics Price Competition and Innovation Act (BPCI Act), which created an abbreviated pathway for the approval of biosimilars and interchangeable biological products.
The newly issued draft guidance expands the existing question-and-answer format to address common regulatory and scientific considerations encountered during biosimilar development. The document reflects the FDA’s evolving regulatory thinking and provides additional clarity on issues such as biosimilar product development strategies, regulatory submissions, and interactions with the agency. It also incorporates updated information relevant to both sponsors and stakeholders involved in the biosimilar approval process.
This guidance has been prepared jointly by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), highlighting the collaborative regulatory oversight of biologics and biosimilar products within the FDA.
KEYWORDS: Biosimilar, Biologics, Approval Process
REFERENCE: https://www.fda.gov/media/119278/download https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable